Product Information
CIBINQO 100 MG TABLET is a brand product labeled by Pfizer Inc., priced at $197.0924 per EA under NDC 00069033530. Its NADAC has been published 98 times since Nov 20, 2024.
FDA first approved this application on Jan 14, 2022.
Strength
100 mg/1
Manufacturer
Pfizer Inc.NDC
00069033530
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ABROCITINIBApproval Type
New Drug (NDA)
FDA Application
NDA213871FDA Approved
1/14/2022
On Market Since
2/24/2022
Pharmacological Classes
Price Statistics
The NADAC for CIBINQO 100 MG TABLET has been published 98 times since Nov 20, 2024, and over the history we have for it it has risen 9.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $197.0924 per EA |
|---|---|
| All-time high | $197.1952 (Jun 10, 2026) |
| All-time low | $180.0955 (Nov 20, 2024) |
| 52-week high | $197.1952 |
| 52-week low | $186.0878 |
| Median price | $189.3303 |
| Average price | $191.5285 |
| Largest weekly change | +5.5% (Dec 31, 2025) |
| Weeks tracked | 98 |
| Tracking since | Nov 20, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the abrocitinib market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
abrocitinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Janus Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CIBINQO 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CIBINQO 100 MG TABLET, manufactured by Pfizer Inc., is $197.0924 per EA (NDC 00069033530), effective Sep 30, 2026.
How has the price of CIBINQO 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for CIBINQO 100 MG TABLET has risen 9.4%. It has been tracked across 98 weekly CMS publications since Nov 20, 2024.
What are the highest and lowest recorded NADAC prices for CIBINQO 100 MG TABLET?
Since Nov 20, 2024, the NADAC for CIBINQO 100 MG TABLET has ranged from a low of $180.0955 (Nov 20, 2024) to a high of $197.1952 (Jun 10, 2026), with a median of $189.3303 per EA.
Are there cheaper alternatives to CIBINQO 100 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CIBINQO 100 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CIBINQO 100 MG TABLET?
CIBINQO 100 MG TABLET (NDC 00069033530) is labeled by Pfizer Inc., and CMS classifies it as a brand product.